Observational Study
Copyright ©The Author(s) 2022.
World J Gastroenterol. Mar 7, 2022; 28(9): 961-972
Published online Mar 7, 2022. doi: 10.3748/wjg.v28.i9.961
Table 1 Patients’ characteristics according to clinical remission status

Clinical remission, n (%) unless otherwise specified
No, n = 19
Yes, n = 15
Female sex10 (53%)6 (40%)
Age (yrs), Med [IQR]34 [27-38]35 [23-44]
BMI, Med [IQR]28 [19-32]22 [20-23]
Number of comorbidities1, Med [IQR]0 [0-1]0 [0-1]
Active smoking, 1 MD9 (47%)6 (43%)
Crohn’s disease phenotype (Montreal L)
Terminal ileum3 (16%)4 (27%)
Colon8 (42%)5 (33%)
Ileo-colon8 (42%)5 (33%)
Upper digestive tract0 (0%)1 (7%)
Crohn’s disease phenotype (Montreal B)
Non-stricturing, non-penetrating12 (63%)8 (53%)
Stricturing4 (21%)2 (13%)
Penetrating2 (11%)2 (13%)
Stricturing + penetrating1 (5%)3 (20%)
Number of fistulas, Med [IQR]2 [1-2]2 [1-2]
Complex fistula17 (89%)11 (73%)
Vaginal fistula4 (21%)1 (7%)
Previous treatment with infliximab10 (53%)7 (47%)
Previous treatment with another anti-TNF-α210 (53%)7 (47%)
Previous treatment with another form of biotherapy310 (53%)7 (47%)
Previous treatment with combination therapy12 (63%)5 (33%)
Previous abdominal surgery
No14 (74%)11 (73%)
Appendicectomy0 (0%)2 (13%)
Ileocecal resection4 (21%)2 (13%)
Colectomy1 (6%)0 (0%)
Previous fistulotomy4 (21%)6 (40%)
Previous seton18 (95%)13 (87%)
Previous flattening of abscesses8 (42%)10 (67%)
Previous closure techniques3 (16%)5 (33%)
Previous glue2 (11%)4 (27%)
Previous plug0 (0%)1 (7%)
Previous rectal advancement flap1 (5%)0 (0%)
Optimization at first visit8 (42%)9 (60%)
Combination therapy (with methotrexate or thiopurine) at first visit12 (63%)5 (33%)
Combination therapy and/or optimization at first evaluation15 (79%)9 (60%)

  • Citation: Sirmai L, Pelletier AL, Gault N, Zallot C, Bouguen G, Bouchard D, Roland Nicaise P, Peyneau M, Sironneau S, Bittencourt MDC, Petitcollin A, Fernandez P, Roblin X, Siproudhis L, Abramowitz L. Relationship between clinical remission of perianal fistulas in Crohn’s disease and serum adalimumab concentrations: A multi-center cross-sectional study. World J Gastroenterol 2022; 28(9): 961-972
  • URL: https://www.wjgnet.com/1007-9327/full/v28/i9/961.htm
  • DOI: https://dx.doi.org/10.3748/wjg.v28.i9.961